NYSEARCA:XBISPDR S&P Biotech ETF Stock Price, Forecast & News

SPDR S&P Biotech ETF's stock was trading at $79.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XBI stock has increased by 47.6% and is now trading at $116.6202. View which stocks have been most impacted by Coronavirus.

SPDR S&P Biotech ETF announced a quarterly dividend on Friday, December 20th. Investors of record on Monday, December 23rd will be paid a dividend of $0.0009 per share on Thursday, December 26th. This represents a $0.00 dividend on an annualized basis and a yield of 0.00%. The ex-dividend date is Friday, December 20th. View SPDR S&P Biotech ETF's dividend history.

Press coverage about XBI stock has been trending negative recently, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SPDR S&P Biotech ETF earned a news impact score of -2.1 on InfoTrie's scale. They also assigned media stories about the exchange traded fund a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about SPDR S&P Biotech ETF.

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include iShares Nasdaq Biotechnology ETF (IBB), NVIDIA (NVDA), Netflix (NFLX), Walt Disney (DIS), Intel (INTC), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Cisco Systems (CSCO) and Pfizer (PFE).

SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."

SPDR S&P Biotech ETF's stock is owned by many different retail and institutional investors. Top institutional investors include Carnegie Capital Asset Management LLC (0.15%), Courier Capital LLC (0.07%), Envestnet Asset Management Inc. (0.04%), M&R Capital Management Inc. (0.04%), Ayalon Holdings Ltd. (0.03%) and Wiley BROS. Aintree Capital LLC (0.01%).

XBI stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Courier Capital LLC, Wiley BROS. Aintree Capital LLC, and Wealth Alliance Advisory Group LLC.

XBI stock was bought by a variety of institutional investors in the last quarter, including Ayalon Holdings Ltd., M&R Capital Management Inc., N.E.W. Advisory Services LLC, Clarus Wealth Advisors, Private Trust Co. NA, Carnegie Capital Asset Management LLC, and Tsfg LLC.

Shares of XBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XBI stock can currently be purchased for approximately $116.62.

SPDR S&P Biotech ETF has a market capitalization of $6.04 billion.

The official website for SPDR S&P Biotech ETF is www.spdrs.com.

SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The exchange traded fund can be reached via phone at +1-866-7872257.